finwire.io
Insider Trading News

10% owner ARCH Venture Fund XIII, L.P. adds $25M of Lyell Immunopharma, Inc. stock

By Insider Stock Trader Newsroom1 min readInsider Stock Trader
10% owner ARCH Venture Fund XIII, L.P. adds $25M of Lyell Immunopharma, Inc. stock10% owner ARCH Venture Fund XIII, L.P. adds $25M of Lyell Immunopharma, Inc. stock

The 10% owner paid an average of $10.77 a share, according to a Form 4 filed with the SEC on Nov 5. Information only, not investment advice.

ARCH Venture Fund XIII, L.P., a holder of more than 10% of Lyell Immunopharma, Inc. (LYEL), bought 2,321,262 shares on Nov 4 at an average price of $10.77, a total of $25 million, according to a Form 4 filed on Nov 5.

The filing reports the shares as held indirectly, for example through a trust or a fund. With this purchase the insider holds 3,747,790 shares, 163% more than before.

The trade was reported within two business days, as Section 16 requires.

Figures come from the Form 4 filed with the SEC; the table lists the open-market rows this article covers.

The purchase
CompanyLyell Immunopharma, Inc. (LYEL)
InsiderARCH Venture Fund XIII, L.P.
Role10% owner
TransactionOpen-market purchase (code P)
Shares2,321,262
Average price$10.77
Value$24,999,992
Trade dateNov 4, 2026
Filed with the SECNov 5, 2026, 5:34 PM ET
Shares held after3,747,790
OwnershipIndirect
Rule 10b5-1 planNot marked in the filing

See the detailed report on this LYEL purchase

View the Form 4 on SEC.gov

Follow LYEL for the next insider trade · See all the latest insider trades

Source: SEC Form 4. Information only, not investment advice. Not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Related Articles